Compare Cisco Systems Inc (CSCO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs BIO-TECHNE Corp — how do they compare? Cisco Systems Inc trades at $121.02 (market cap $483.10B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Cisco Systems Inc is far larger — about 43× BIO-TECHNE Corp's market cap, and Cisco Systems Inc pays the higher dividend (1.37%). Which is the better fit depends on your goals.
| CSCO | TECH | |
|---|---|---|
Market Cap | $483.10B | $11.24B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $72.29 |
52-Week Low | $66.20 | $43.31 |
Enterprise Value | $497.76B | $11.32B |
Dividend Yield | 1.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $121.43, up 0.45% today and near its 52-week high, supported by a bullish technical outlook and strong earnings beats. The stock's valuation is elevated with a P/E of 40.48 and P/S of 7.97, but profitability remains solid with a 64.33% gross margin. Recent news highlights Cisco's strategic push into AI cybersecurity, with new partnerships and product launches driving positive sentiment.
The outlook is positive given analyst consensus and AI-driven growth initiatives, but risks include high valuation and competitive pressures. Upside to the $133.25 price target is plausible if execution continues, though investors should monitor debt levels and margin trends.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
